TICKERNERD
Menu
LCTXLCTXHealthcare · Biotechnology

LCTX Stock Forecast: Lineage Cell Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.01
−0.98% on the day

The 7 Wall Street analysts covering Lineage Cell Therapeutics, Inc. hold a median 12-month price target of $4.5 — +345.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$255.4M
Ticker Nerd rank
55 / 100
Median analyst target
$4.50
Analysts covering
7
Revenue$1.1M−61.3% y/y
Operating income−$8.9M
Net income$1.5M
Free cash flow−$7.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.2%
1M
−9.8%
YTD
−39.5%
1Y
−21.7%
From 52W high
−48.5%
From 52W low
0.0%
$1.01
$1.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LCTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lineage Cell Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
71
Quality
67
Value
67
Growth
66
Size
65
Momentum
50
Accruals
47
Revisions
35
Issuance
31

Volatility (71): The share price has been relatively steady.

Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LCTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LCTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26LCTXHigh $9.00Median $4.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $3.00Median $4.50High $9.00

The green dot is the last close — the median target sits +345.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 July 2026HC Wainwright & Co.ReiteratesBuy—
4 May 2026D. Boral CapitalMaintainsBuy—
28 Apr 2026Canaccord GenuityInitiatesBuy—
25 Mar 2026B. Riley SecuritiesMaintainsBuy—
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
6 Mar 2026D. Boral CapitalMaintainsBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy—
25 Nov 2025D. Boral CapitalMaintainsBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
14 Aug 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025D. Boral CapitalMaintainsBuy—
23 June 2025D. Boral CapitalMaintainsBuy—
23 June 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025B. Riley SecuritiesMaintainsBuy—
11 Mar 2025D. Boral CapitalMaintainsBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025D. Boral CapitalMaintainsBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
31 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LCTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LCTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Lineage Cell Therapeutics, Inc. returned −21.7% against +17.5% for the S&P 500, dividends included.

LCTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26LCTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LCTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Lineage Cell Therapeutics, Inc. (LCTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.7×

Cheaper than 88% of US stocks

Price / sales
20.3×

Cheaper than 9% of US stocks

Price / book
4.4×

Cheaper than 24% of US stocks

EV / EBITDA
−7.9×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
−61.3%

Higher than 4% of US stocks

Earnings growth (YoY)
−61.3%

Higher than 8% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−834.7%

Higher than 6% of US stocks

Net margin
−246.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−60.1%

Higher than 19% of US stocks

Return on assets
−17.0%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lineage Cell Therapeutics, Inc. (LCTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lineage Cell Therapeutics, Inc. has a market value of $255.4M and an enterprise value of $205.8M.

  • Revenue in the twelve months to 30 June 2026: $13.1M. The latest quarter shrank 61.3% year on year.

  • Net income over the same four quarters: −$32.1M, a −245.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$24.4M.

  • Lineage Cell Therapeutics, Inc. spent $41K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 252.9M.

  • Trailing P/E: −3.7×; forward P/E: −10.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lineage Cell Therapeutics, Inc. employs 72 people — $182K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

LCTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LCTXLineage Cell Therapeutics, Inc.$255.4M
55
MGNXMacroGenics, Inc.$254.2M
65
PRQRProQR Therapeutics NV$256.8M
43
FHTXFoghorn Therapeutics, Inc.$258.9M
69
VRXAVERAXA Biotech AG$243.8M
20
AVXLAnavex Life Sciences Corp.$242.8M
25
RNACCartesian Therapeutics, Inc.$240.0M
24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lineage Cell Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LCTX news & analysis

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

Business Wire · 8 Sept 2026positive

Lineage Cell Therapeutics announced the issuance of a patent underlying its AlloSCOPE 5D manufacturing platform. The announcement was made via Business Wire from the company's Carlsbad, California headquarters.

Why it matters — A patent covering the AlloSCOPE 5D platform helps protect the company's manufacturing technology, an important element of its cell-therapy operations.

Lineage Cell Therapeutics Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Lineage Cell Therapeutics reported progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs. Roche and Genentech continue optimization work on surgical delivery for the company's lead OpRegen program.

Why it matters — LCTX watchers would care because the call confirms continued pipeline advancement and ongoing partner work on the lead OpRegen program, signaling development momentum across multiple cell-therapy candidates.

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Lineage Cell Therapeutics, Inc. (LCTX) held its Q2 2026 earnings call, and a transcript of that call has been published on Seeking Alpha. The transcript covers the company's quarterly financial and operational update.

Why it matters — LCTX watchers would find the earnings call transcript a primary source for management's latest commentary on the company's performance and outlook.

Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Lineage Cell reported a second-quarter loss of $0.03 per share, matching the Zacks Consensus Estimate but wider than the $0.01 per share loss a year earlier, while revenue lagged consensus estimates.

Why it matters — A LCTX watcher would care because the widened quarterly loss and revenue that fell short of estimates signal weaker-than-expected recent financial performance.

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Business Wire · 6 Aug 2026neutral

Lineage Cell Therapeutics, Inc. reported its financial results for the second quarter of 2026 and provided a business update. The announcement was distributed via Business Wire from the company's Carlsbad, California location.

Why it matters — A shareholder would check this announcement for updates on the company's financial performance and the progress of its business operations and pipeline.

FAQ

Frequently asked questions about LCTX stock

What is the LCTX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Lineage Cell Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LCTX stock a buy right now?

Of the 7 analysts covering Lineage Cell Therapeutics, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lineage Cell Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LCTX?

As at 12 Sept 2026, Lineage Cell Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (71 of 100).

Will LCTX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +345.5% from the last close, and Ticker Nerd's factor model ranks Lineage Cell Therapeutics, Inc. 55 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LCTX stock forecast for 2030?

No analyst covering Lineage Cell Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LCTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.

How has LCTX stock performed over the past year?

Lineage Cell Therapeutics, Inc. returned -21.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lineage Cell Therapeutics, Inc. do?

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or off-the-shelf, cell therapies for serious medical conditions.

What is the latest news on LCTX?

The most recent item we track (Business Wire, 8 Sept 2026): "Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform". Lineage Cell Therapeutics announced the issuance of a patent underlying its AlloSCOPE 5D manufacturing platform. The announcement was made via Business Wire from the company's Carlsbad, California headquarters.

Company

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or off-the-shelf, cell therapies for serious medical conditions. Its current programs center on cell replacement therapies for ophthalmology, neurology, hearing loss, and corneal disease, with product candidates designed to restore or replace damaged cells in targeted tissues. The company’s pipeline includes OpRegen for retinal disorders, OPC1 for spinal cord injury, COR1 for corneal endothelial disease, and other platform-based programs supported by its proprietary manufacturing and delivery capabilities. Lineage Cell Therapeutics, Inc. works at the intersection of regenerative medicine and specialty therapeutics, addressing areas of high unmet medical need through pluripotent stem cell-based technologies.

CEO Mr. Brian M. Culley M.A., M.B.A. · 72 employees · United States · https://www.lineagecell.com